Pay in 4 interest-free payments of $26.25 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
8-dihydroxy-2H-1-benzopyran-2-one
α2-adrenergic (pKi = 7
5E)-1-((S)-2-amino-3-phenylpropanoyl)-3
Chakrabarti G
Heclin does not block E2 binding but causes a conformational change that results in oxidation of the active site Cys
Ruxolitinib (S) 05 trifluoroacetate 8-dihydroxy-2H-1-benzopyran-2-oneS Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive
US$ 897.50
US$ 677.00
US$ 1624.50
US$ 897.50